

a 2013 0005

The invention relates to a pharmaceutical composition for prolonged release of trimetazidine, wherein an inner phase comprises trimetazidine and an outer layer comprises a retardant and an anti-agglomerant.

The forms with prolonged release, according to the invention, provides a gradual and sustained release of trimetazidine over 24 hours at a therapeutic efficacious plasma concentration and an availability of trimetazidine at a therapeutic efficacious plasma concentration following the administration.

It is also described a process for manufacture of a composition and use thereof in the prophylactic treatment of angina pectoris, in the course of chorioretinal disorders and also in the treatment of vertigo of vascular origin.

Claims: 21

Fig.: 5